Cancer Network Staff

Results from the phase 3 RASolute 302 trial showed that daraxonrasib improved median OS compared with standard chemotherapy in metastatic PDAC.

The FDA cited that the data provided for RP1 were insufficient and did not provide substantial evidence of effectiveness for this population.

The FDA has removed the partial clinical hold on the phase 2 LINNET study of lorigerlimab for patients with platinum-resistant ovarian cancer and clear cell gynecologic cancer.

The FDA has also approved the BD Onclarity HPV Assay for the screening of cervical cancer, with support from the SHIP trial evaluating at-home cervical cancer screening.

Treatment with Rhenium-186 Obisbemeda for pediatric malignant gliomas and ependymomas is being assessed in the ReSPECT-PBC trial.

The FDA granted fast track designation to SIM0505, a CDH6-directed antibody-drug conjugate, for the management of platinum-resistant ovarian cancer.

The FDA has granted orphan drug designation to tovecimig (CTX-009) for the treatment of bile duct cancer, following results from the phase 2/3 COMPANION-002 trial.

The 2026 ASCO thyroid cancer guideline update focused on the shifting landscape of systemic therapy for advanced disease.

Mina Fam, MD, explored the integration of multiparametric MRI and genomics in focal HIFU selection and compared its AE profile to radical intervention.

Robert Coleman, MD, FACOG, FACS, discusses the significance of the relacorilant and nab-paclitaxel approval in PROC supported by phase 3 ROSELLA trial data.

The FDA granted FTD to CTIM-76, a CLDN6/CD3 bispecific antibody, for the treatment of patients with CLDN6-positive platinum-resistant ovarian cancer.

Results from a phase 1/2a trial and the ongoing FORTE basket study support the FDA’s regulatory decision for these patients with recurrent or progressive glioma.

The phase 3 EMERALD-3 trial met its primary end point of PFS with durvalumab, tremelimumab, lenvatinib, and TACE in patients with unresectable HCC.

Management strategies for oxybutynin-induced xerostomia include hydration, sugar-free gum, and humidification.

BiliSeqV2/V3 improved neoplastic bile duct stricture identification compared with pathology alone, according to a study from UPMC investigators.

Results from the phase 1/2 ReFocus trial demonstrated positive activity from lirafugratinib in the various pretreated, FGFR2-mutated cholangiocarcinoma populations.

ZW191 is currently under evaluation in a phase 1 trial that has already demonstrated activity among patients with platinum-resistant ovarian cancer.

Linda Carlson, PhD, RPsych, explored the shift from efficacy to implementation in integrative oncology, emphasizing behavioral interventions.

Adding atezolizumab to adjuvant FOLFOX significantly improves disease-free survival for patients with stage III mismatch repair-deficient colon cancer.

Updated data demonstrated a 14.7-month OS benefit when adding IMNN-001 to neoadjuvant chemotherapy in patients with newly diagnosed ovarian cancer.

Rahul Aggarwal, MD, discussed the high unmet needs of neuroendocrine prostate cancer, highlighting biopsy triggers, genomic markers, and emerging targets.

ECG changes and cardiac biomarkers were evaluated in patients with breast cancer to identify early markers of chemotherapy-induced cardiotoxicity.

The FDA has cleared an investigator-initiated investigational new drug application for a first-in-class AAV immuno-gene therapy in recurrent high-grade glioma.

Germline platelet polygenic risk score predicted a 37% higher risk of death in patients with renal cell carcinoma, mediated by sustained thrombocytosis.

Three Neuroendocrine Tumor Research Foundation grant winners outlined research that aimed to deliver biology-driven strategies to patients.

FG001 is an investigational uPAR-targeting fluorophore designed to provide real-time illumination of aggressive brain tumors during surgical resection.

Sacituzumab govitecan and pembrolizumab were recommended as category 1 regimens for metastatic triple-negative breast cancers based on 2 phase 3 trials.

The irinotecan-based ChemoSeed delivery mechanism is currently under investigation for patients with malignant glioma in a registrational phase 2 trial.

Julian Hong, MD, MS, discussed an analysis showing that patients with cancer and new mental health disorders have an increased risk of all-cause mortality.

Results from a phase 1b trial for givastomig in frontline HER2-negative, PD-L1–positive gastroesophageal cancer support the FDA’s decision.